Sodium-glucose cotransporter-2 inhibitor (SGLT2i)-associated euglycaemic diabetic ketoacidosis (euDKA) is a serious and increasingly recognised complication of treatment with this class of oral hypoglycaemic agents and can present a diagnostic challenge, resulting in delayed recognition, inappropriate treatment and potentially life-threatening acidosis. We present two cases of patients developing SGLT2i-associated euDKA in the early postoperative period. We support ceasing SGLT2i for 72 hours preoperatively and would suggest continuing to withhold the medication until oral intake is restored, and recommend a wider awareness of SGLT2i-associated diabetic ketoacidosis (DKA) amongst patients and their healthcare providers with an emphasis on checking ketone levels irrespective of blood glucose levels in the postoperative setting.
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Summary
Sodium-glucose cotransporter-2 inhibitor (SGLT2i)-associated euglycaemic diabetic ketoacidosis (euDKA) is a serious and increasingly recognised complication of treatment with this class of oral hypoglycaemic agents and can present a diagnostic challenge, resulting in delayed recognition, inappropriate treatment and potentially life-threatening acidosis. We present two cases of patients developing SGLT2i-associated euDKA in the early postoperative period. We support ceasing SGLT2i for 72 hours preoperatively and would suggest continuing to withhold the medication until oral intake is restored, and recommend a wider awareness of SGLT2i-associated diabetic ketoacidosis (DKA) amongst patients and their healthcare providers with an emphasis on checking ketone levels irrespective of blood glucose levels in the postoperative setting.
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Euglycaemic diabetic ketoacidosis (euDKA) can be a serious complication of treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) and can potentially cause life-threatening metabolic acidosis in critically ill patients, including those in the perioperative setting. EuDKA can present a diagnostic challenge and may lead to both delayed recognition and inappropriate treatment. We describe two cases of euDKA developing in patients on SGLT2i in the perioperative period and review existing literature to arrive at recommendations for clinical practice. Both patients have consented for details to be published in this article.
Case one
A 55-year-old male was transferred to the intensive care unit (ICU) from a peripheral hospital with severe, unexplained metabolic acidosis. He was diagnosed with type 2 diabetes mellitus (T2DM) six years previously and managed with oral hypoglycaemic agents (empagliflozin, metformin and linagliptin). Other medical history included ischaemic heart disease with previous coronary artery bypass grafting, osteoarthritis, hypertension and post-traumatic stress disorder from military service. Six days prior to ICU admission, he had undergone an elective and uncomplicated total knee replacement. Postoperatively, despite poor oral intake, his usual oral hypoglycaemic agents were continued. He developed a worsening metabolic acidosis, tachypnoea, polyuria and dehydration. On transfer to ICU an arterial blood gas showed severe metabolic acidosis with pH 7.08, PaCO 2 10 mmHg, HCO 3 6.5 mmol/l, base excess -26.2 mmol/l, anion gap 20 mmol/l, lactate 1.0 mmol/l and glucose 10.0 mmol/l. Sodium bicarbonate infusion was commenced along with correction of electrolyte abnormalities. However, the metabolic acidosis worsened. His blood glucose levels remained around 10.0 mmol/l while his renal function remained normal. Eventually blood ketone levels were found to be elevated at 2.0 mmol/l (normal <0.5, high >1.6 mmol/l). Treatment for diabetic ketoacidosis (DKA) was commenced with an insulin and dextrose infusion. All three oral hypoglycaemic agents were discontinued. His acidosis resolved and clinical condition improved over a 24-hour period. He was transitioned to a subcutaneous insulin regimen. Negative anti-glutamic acid decarboxylase antibody titres excluded type 1 diabetes mellitus (T1DM). He was discharged from ICU on day five and went home on day seven. At follow-up, insulin was weaned with reintroduction of metformin and gliclazide, which was sufficient to maintain glycaemic control. 
Case two
A 66-year-old female was admitted to the ICU following elective coronary artery bypass surgery. She was known to have T2DM, treated with oral hypoglycaemic agents including saxagliptin, metformin and dapagliflozin for several years. Other medical history included hypertension, obesity, minor carotid artery disease, previous breast cancer and an anxiety disorder.
She had an uncomplicated procedure and was transferred to ICU ventilated and sedated. As per protocol, she was weaned and extubated on day zero. She was haemodynamically stable. A low-dose soluble insulin infusion (Actrapid®, two units/hour) had been used to maintain euglycaemia. This had been weaned off within the first few hours based on her blood glucose levels and the local insulin infusion policy. Approximately 20 hours after returning from theatre, she quite precipitously developed a high anion gap metabolic acidosis with respiratory compensation (pH 7.26, HCO 3 13.3 mmol/l, base excess -12.6 mmol/l, PaCO 2 30.2 mmHg, glucose 9.2 mmol/l, lactate 1.13 mmol/l). Renal function was within the normal range (estimated glomerular filtration rate >90 ml/min) with adequate urine output. Modest oral intake of a diabetic diet had been established. An insulin infusion of two units/hour was recommenced when her blood glucose level had risen to 10.2 mmol/l. Blood ketones were elevated at 1.8 mmol/l. A diagnosis of euDKA was established. Metformin, saxagliptin and dapagliflozin were ceased. Treatment with an insulin/dextrose infusion was commenced with steady improvement in her acidosis.
Unfortunately, she required reintubation the following morning. This was likely due to a combination of postoperative pain, atelectasis, anxiety, new-onset atrial fibrillation and possibly the respiratory compensation for worsening DKA with weaning of the insulin/dextrose infusion. Treatment continued with titration of insulin/dextrose based on blood ketone rather than blood glucose levels and resulted in resolution of the acidosis. The overall condition of the patient improved and she was extubated day two postoperatively. She was transitioned onto a regimen of both short-and long-acting subcutaneous insulin. Again, antiglutamic acid decarboxylase antibody titres were negative. She was transferred to the ward day five postoperatively for ongoing care.
Discussion
SGLT2i are the newest class of oral hypoglycaemic agents available for the treatment of T2DM. The sodium-glucose cotransporter is selectively expressed in the kidney and is responsible for reabsorption of glucose from the proximal renal tubule. The inhibition of this transporter therefore leads to increased glycosuria and decreased plasma glucose levels, and promotes weight loss (Figure 1 ). SGLT2i have a lower tendency to cause hypoglycaemia as they do not affect endogenous glucose production in response to hypoglycaemia and the degree of glucuresis is dependent on both glomerular filtration and blood glucose levels 1 . The effects of SGLT2i are insulin-independent, making them suitable for use at any stage of T2DM and potentially, T1DM 2 . Empagliflozin and canagliflozin have been shown in outcome trials to decrease the risk of major adverse cardiovascular events in patients with T2DM 3 . The mild metabolic shift from glucose to ketone body use has been postulated to be a more efficient energy source, which improves cardiac and renal efficiency thus improving cardiac contractility and renal function. This, in combination with weight loss and reduction in blood pressure, are proposed to contribute to the cardiovascular benefits 4 . The American Diabetes Association and American Association of Clinical Endocrinologists (AACE) recommend the use of SGLT2i as either adjuvant therapy with metformin, first-line therapy for those who are intolerant to metformin, or in combination with insulin therapy 5 . Table 1 outlines brand names of the commonly used SGLT2i.
During the first 14 months of SGLT2i approved use in the United States, 20 cases of DKA were reported, prompting a US Food and Drug Administration (FDA) alert outlining this potential risk 6 . Shortly thereafter, the European Medicines Agency identified about 147 cases of DKA in patients treated with SGLT2i . As a consequence, in December 2015, manufacturers were required to update labelling of products to include a warning of potential DKA. The US FDA also . Based on the profile of the case reports, Fadini et al concluded SGLT2i-associated DKA may not be limited to any particular demographic or comorbid subpopulation and can occur at any duration of SGLT2i use 9 . Of concern, DKA was fatal in 37 patients 9 . Bonora et al 10 in their narrative case reports illustrate that SGLT2i-associated DKA can occur in patients with T1DM incorrectly diagnosed as T2DM. Their literature review of 105 SGLT2i-associated DKA case reports revealed true euglycaemic DKA in only 35% of cases. An incidence of less than 1/1,000 in randomised controlled trials and 1.6/1,000 patient-years in cohort studies was noted, but higher rates were expected in true clinical practice 10 . Goldenberg et al 11 have extensively reviewed SGLT2i-associated DKA and set out practical recommendations for diagnosis and prevention. They conclude that SGLT2i-associated DKA is rare, usually triggered by known precipitants, and can be prevented by appropriate prescribing, withholding SGLT2i when indicated, and counselling patients about sick day management.
DKA is defined as the triad of hyperglycaemia (>14 mmol/l), metabolic acidosis with an elevated anion gap and elevated plasma ketones. SGLT2i-associated DKA is somewhat different in its pathogenesis, though treatment principles are the same. The term 'euglycaemic' DKA has been used when describing SGLT2i-associated DKA, but could be a misnomer as euglycaemia is not universal and is actually uncommon 8, 10 . However, it is notable that the average blood glucose levels in SGLT2i-associated DKA were lower than in the rare cases of DKA seen in T2DM and in DKA seen in T1DM. The mild to modest hyperglycaemia seen with SGLT2i-associated DKA has been identified as a cause for delayed diagnosis and is the basis for educating patients and clinicians to check ketones when a diabetic patient is unwell irrespective of blood glucose levels.
Various authors have elaborated the mechanism of DKA associated with SGLT2i [11] [12] [13] [14] . Figure 2 summarises the succession of events that likely culminates in SGLT2i-associated DKA in T2DM 11 . Ketone accumulation in SGLT2i-associated DKA is downstream of insulin deficiency and glucagon elevation promoting lipolysis and hepatic ketogenesis. SGLT2i-enhanced glycosuria effectively lowers plasma glucose levels, which decreases insulin secretion from pancreatic beta cells. SGLT2i-mediated glycosuria and attenuation of sodium reabsorption in the kidneys may also indirectly expand the ketone reservoir by enhancing renal ketone reabsorption.
A number of factors could precipitate SGLT2i-associated DKA and include but are not limited to: underlying undiagnosed T1DM or latent autoimmune diabetes of adulthood, major surgery, relative or absolute insulin deficit (including dose reduction, cessation of therapy and insulin pump failure), poor carbohydrate intake, infection, alcohol use, physical exercise and corticosteroid use 15 . Precipitating factors, however, were only identified in 78.1% of cases 10 . The cases presented here exemplify major surgery as a precipitating factor in the development of SGLT2i-associated DKA and the need for further understanding of the safe use of SGLT2i in the perioperative period. Twenty-eight percent of cases in a systematic review of SGLT2i-associated DKA in the literature were precipitated by surgery 15 . The physiological stress of surgery commonly increases insulin requirements due to catecholamine release, cortisol production and reduced insulin secretion and utilisation. The ongoing glycosuria due to SGLT2 inhibition may therefore mask these increased actual insulin requirements.
The cases described here also highlight the lack of understanding of the safe use of SGLT2i in the perioperative period and the danger of a delayed diagnosis of euDKA. The first consideration in the safe use of SGLT2i in the perioperative period is the expected duration of the metabolic effects of SGLT2i. This remains unclear. In the cases presented, the first patient was still taking the SGLT2i when he developed euDKA, while the second patient had taken hers until the day before surgery. Therefore, it must be assumed that both patients were still experiencing the effects of the medications. Also, this likely prolonged drug activity duration may dictate a longer duration of treatment for euDKA than suggested by the manufacturer's estimation of half-life (11 to 13 hours). As was seen in both cases, treatment with insulin and dextrose was required for several days to achieve resolution of euDKA and in both cases, ketosis worsened on attempts at weaning therapy. The AACE and American College of Endocrinology (ACE) recommend ceasing SGLT2i 24 hours prior to elective surgery, invasive procedures or stressful activity 16 . However, given the average half-life of the currently approved SGLT2i (empagliflozin, canagliflozin and dapagliflozin) is 12.5 hours, withholding SGLT2i for four to five half-lives (i.e. 50 to 62 hours) is more likely to ensure the drug is no longer having a metabolic effect at the time of surgery. At this stage, the packaging of currently approved SGLT2i does not recommend withholding therapy prior to surgery, only that doing so may reduce the risk of DKA. Given the advice of the AACE/ACE and the evidence presented in the literature, this may need to be revised.
Our recommendation is to withhold SGLT2i for the two days prior to the day of surgery, possibly with bridging therapy with insulin/dextrose to prevent the development of euDKA as required 17 . Furthermore, the development of perioperative guidelines for the safe use of SGLT2i is imperative as pointed out by Hoffman et al 18 . Table 2 summarises the suggested perioperative recommendations for patients on SGLT2i (adapted from Lau et al 19 ). Another concern raised in both cases is the innate diagnostic dilemma of euDKA. Given that glucose levels were normal to only mildly elevated, it might seem counterintuitive to check ketone levels, thus delaying the recognition of ketoacidosis as the cause for high anion gap metabolic acidosis. Failure to recognise euDKA may also lead to incorrect treatment, as was seen with the first patient, who received a sodium bicarbonate infusion without improvement.
Rosenstock et al describe euDKA associated with SGLT2i as "predictable, detectable and preventable" 20 . They recommend that both clinicians and patients need to be aware that any patient treated with SGLT2i who feels unwell should have ketone levels checked irrespective of the blood glucose level. It is disquieting that in most cases presented in the literature, as well as both cases presented here, there was a delay to diagnosis of this life-threatening condition. This suggests that these recommendations are still not widely known or followed. We strongly support these recommendations and urge raising awareness of this condition amongst clinicians as a patient safety priority.
In conclusion, the cases presented here of euDKA associated with the use of SGLT2i highlight the concerns surrounding their potentially life-threatening adverse effects on patients in the perioperative period. Efforts to understand the pharmacodynamics of the SGLT2i class during physiological stress continues. Guiding their safe use, not only perioperatively but when any stress occurs, is imperative. At the very least, SGLT2i should be withheld for a minimum of 72 hours preoperatively and then until normal oral intake resumes postoperatively. The suggested perioperative guidelines are a good starting point. Furthermore, a wider awareness of SGLT2i-associated DKA should be made amongst patients and their healthcare providers, with an emphasis on checking ketone levels irrespective of blood glucose levels when these patients present to facilitate early detection of this life-threatening condition. Table 2 Suggested perioperative recommendations in patients on sodium-glucose cotransporter-2 inhibitors
Major elective surgical procedures SGLT2i should be discontinued 3 days preoperatively, with the last dose taken no less than 55 to 65 hours prior to the surgery.
Postoperative
SGLT2i administration be withheld until adequate hydration and normal diet resumes.
Avoid overt discontinuation or rapid reduction of insulin dose as this could precipitate DKA.
Optimise analgesia and maintain euvolaemia to minimise counterregulatory hormone stimuli, which could potentially increase the risk of DKA.
Frequent monitoring of blood ketones as urine ketones may be unreliable.
If euDKA occurs, manage as DKA, with volume resuscitation with crystalloids, correction of electrolyte abnormalities, and insulin infusion with dextrosecontaining intravenous solutions to limit further lipolysis and ketogenesis.
Emergency surgical procedures Discontinue SGLT2i as soon as possible and accept higher risk for DKA with vigilant monitoring postop. Consider bridging therapy with insulin/dextrose to prevent the development of euDKA.
DKA, diabetic ketoacidosis; euDKA, euglycaemic diabetic ketoacidosis; SGLT2i, sodium-glucose cotransporter-2 inhibitors.
